Thu, 02 Aug 2018 04:56:25 GMT
BeiGene gets $903M in HK's secondary listing under new regulations
China's Nasdaq-listed biotech BeiGene raised $903M after pricing the firm's secondary listing in Hong Kong, the first under new regulations of exchange, three sources close to the deal stated.